Nasdaq
$406.00▲ 0.51%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $58.15BShares out 1.400M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
70- 1d agoClosed26.10.24 10:254Ownership#●●●
Natera, Inc.
Insider Jonathan Sheena of Natera, Inc. filed a Form 4 report regarding changes in beneficial ownership of securities as of October 21, 2026. This filing serves as a routine disclosure of insider equity transactions and does not indicate any changes to the company's financial position or business operations.…more
$406.00+0.51%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 3d agoRegular26.10.22 02:09144Ownership
Natera, Inc.
Natera, Inc. insider Sheena Jonathan has filed an SEC Form 144 to report the proposed sale of company shares. This is a standard filing disclosing an insider's plan to dispose of their holdings.…more
$406.00+0.51%vs prev closeView filingShare - 4d agoOvernight26.10.21 10:354Ownership
Natera, Inc.
Natera, Inc. insider Jonathan Sheena reported a change in beneficial ownership of securities as of October 16, 2026. This filing serves as a Form 4 statement regarding the insider's equity holdings.…more
$406.00+0.51%vs prev closeView filingShare
69 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoOvernight26.10.19 15:49#●●●#●●●
Natera to Present SAGITTARIUS Phase III Data at ESMO 2026
Natera will unveil Phase III data at ESMO 2026 showing that Signatera results influenced treatment plans for one-third of colon cancer patients. Notably, 87% of MRD-negative patients were able to de-escalate treatment, demonstrating the clinical utility of the test.…more
$406.00+0.51%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.13Pre-market26.10.13 20:34
●●●●●●●● ●●●●● ●●●●●●
Natera and TransCode Therapeutics have entered a strategic collaboration to support patient enrollment for a Phase 2a clinical trial of TTX-MC138. The partnership will utilize Natera's Signatera test to identify eligible patients with molecular residual disease more efficiently.…more
$406.00+0.51%vs prev closeShareBenzinga - 10.9Pre-market26.10.09 21:02
●●●●●●●● ●●●●● ●●●●●●
Natera's multi-cancer early detection assay has been granted Breakthrough Device designation by the FDA. This designation recognizes the potential of the technology to provide more effective diagnosis for life-threatening conditions.…more
$406.00+0.51%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report